Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
The story of how Novo Nordisk will lose billions because it didn't pay a couple of hundred dollars
04:24am, Monday, 16'th Jun 2025
Novo Nordisk's annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.
Novo Nordisk Is Europe's Most Valuable Company—Again. Eli Lilly, Watch Out.
12:58pm, Friday, 13'th Jun 2025
The Danish drug maker is being more forceful since its CEO departed last month.
The Big 3: NVO, DIS, WHR
12:30pm, Friday, 13'th Jun 2025
Andrew Arons joins today's Big 3 to talk about stocks he believes can make 20% moves over the next year. He sees Novo Nordisk (NVO) benefitting off a rising weight-loss drug trends, Walt Disney (DIS)
NVO Stock up on Plans to Advance Obesity Candidate Amycretin
10:11am, Friday, 13'th Jun 2025
Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.
Novo Nordisk regains crown as Europe's most valuable company
05:08am, Friday, 13'th Jun 2025
Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German software firm SAP on Friday.
After ousting CEO, Novo Nordisk reclaims crown as largest European company
04:48am, Friday, 13'th Jun 2025
Novo Nordisk's shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe's largest by market capitalization.
Why Novo Nordisk (NVO) Outpaced the Stock Market Today
06:46pm, Thursday, 12'th Jun 2025
Novo Nordisk (NVO) concluded the recent trading session at $81.05, signifying a +2.95% move from its prior day's close.
Why Novo Nordisk Stock Pumped Higher on Thursday
06:02pm, Thursday, 12'th Jun 2025
Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NVO 2.96%) stock on Thursday. The Denmark-based pharmaceutical company, famed for its Ozempic and Wegovy drugs, saw it
Novo Nordisk plans to start late-stage trials for experimental obesity drug amycretin
01:22pm, Thursday, 12'th Jun 2025
Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first quarter of 2026 for adults who are overweight or obese.
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
01:06pm, Thursday, 12'th Jun 2025
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studie
Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition
02:00pm, Wednesday, 11'th Jun 2025
Novo Nordisk's drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC's Disruptor 50 List.
NVO Stock Gains After Parvus Asset Management Builds Stake
11:00am, Wednesday, 11'th Jun 2025
Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline buzz.
Why Novo Nordisk Stock Just Popped
01:36pm, Tuesday, 10'th Jun 2025
Novo Nordisk (NVO 6.07%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky 7% through 12:20 p.m. ET Tuesday after London's Financial Times reported loc
Novo Nordisk: The Time To Buy Has Come
01:18pm, Tuesday, 10'th Jun 2025
Despite Novo Nordisk's recent stock slide, strong Q1 FY25 results and strategic initiatives reinforce a "Buy" rating, presenting a continued, albeit tested, investment opportunity for patient investor
Novo Nordisk starts new CagriSema weightloss drug trial
11:13am, Tuesday, 10'th Jun 2025
Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential after disappointing data fr
